This important study presents compelling observational data supporting a role for transcription and polysome accumulation in the separation of newly replicated bacterial chromosomes. The study is ...

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of ...

G6AOTCQB Venture Market (OTCQB): GARWF VANCOUVER, BC, Jan. 29, 2025 /PRNewswire/ – Golden Arrow Resources Corporation (TSXV: GRG) (FSE: G6A) (OTCQB: GARWF), ("Golden Arrow" or the "Company") is ...

To avoid this, anger must align with a vision for positive change. It must remain grounded in purpose and guided by reason, compassion, and an unwavering commitment to the greater good.

Vistagen, a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, announced positive results from an exploratory phase 2A study of PH284 in cancer ...

We're nearing the end of Phase 5 of the MCU which marks the midway point of The Multiverse Saga, following the releases of Agatha All Along and Deadpool & Wolverine in 2024. This year sees the ...

The phase 3 program missed both primary and key secondary endpoints, with no statistically significant effects on relevant measures observed for patients receiving investigational treatment ...

In patients with high-risk HER2-positive breast cancer ... according to the final results of the Phase III KATHERINE clinical trial led by researchers from the University of Pittsburgh and ...

Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer ... The primary analysis of KATHERINE, a phase 3, open-label trial, showed that the risk of invasive ...

Credit: PattyPhoto/Shutterstock. Vistagen has reported positive outcomes from the exploratory Phase IIA trial of an investigational pherine nasal spray, PH284, for the treatment of cancer cachexia.

NEW YORK – Context Therapeutics on Wednesday said it began treating patients in a Phase I trial of its claudin 6 (CLDN6)- and CD3 T-cell-engaging bispecific antibody, CTIM-76, in CLDN6-positive ...